• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients.

作者信息

How Joan, Gallagher Kathleen M E, Liu Yiwen, Katsis Katelin, Elder Eva L, Larson Rebecca C, Leick Mark B, Neuberg Donna, Maus Marcela V, Hobbs Gabriela S

机构信息

Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA.

出版信息

Leukemia. 2022 Apr;36(4):1176-1179. doi: 10.1038/s41375-022-01533-0. Epub 2022 Feb 25.

DOI:10.1038/s41375-022-01533-0
PMID:35217807
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8873343/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526c/8873343/d3ade07ae1ae/41375_2022_1533_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526c/8873343/d3ade07ae1ae/41375_2022_1533_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526c/8873343/d3ade07ae1ae/41375_2022_1533_Fig1_HTML.jpg

相似文献

1
Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients.骨髓增殖性肿瘤患者对SARS-CoV-2疫苗接种的抗体和T细胞反应。
Leukemia. 2022 Apr;36(4):1176-1179. doi: 10.1038/s41375-022-01533-0. Epub 2022 Feb 25.
2
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms.单剂量BNT162b2 mRNA新冠疫苗可在骨髓增殖性肿瘤患者中诱导出高频率的中和抗体及多功能T细胞反应。
Leukemia. 2021 Dec;35(12):3573-3577. doi: 10.1038/s41375-021-01300-7. Epub 2021 May 22.
3
Neutralizing antibody and T cell responses to SARS-CoV-2 vaccination in hematopoietic cell transplant recipients.造血细胞移植受者对SARS-CoV-2疫苗接种的中和抗体和T细胞反应。
Bone Marrow Transplant. 2022 Jul;57(7):1183-1186. doi: 10.1038/s41409-022-01675-w. Epub 2022 Apr 21.
4
Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.慢性透析患者 COVID-19 疫苗接种的免疫原性。
Front Immunol. 2021 Jun 30;12:690698. doi: 10.3389/fimmu.2021.690698. eCollection 2021.
5
mRNA-based COVID-19 vaccination of lung transplant recipients with prior SARS-CoV-2 infection induces durable SARS-CoV-2-specific antibodies and T cells.mRNA 疫苗接种 COVID-19 对有 SARS-CoV-2 既往感染的肺移植受者诱导持久的 SARS-CoV-2 特异性抗体和 T 细胞。
Vaccine. 2024 Oct 24;42(24):126250. doi: 10.1016/j.vaccine.2024.126250. Epub 2024 Sep 2.
6
Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.接种 COVID-19 mRNA 疫苗后，需要数天才能诱导针对 SARS-CoV-2 的高特异性体液和细胞反应。
Front Immunol. 2021 Oct 4;12:726960. doi: 10.3389/fimmu.2021.726960. eCollection 2021.
7
Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab.奥瑞珠单抗治疗多发性硬化症患者对 SARS-CoV-2 疫苗的体液和 T 细胞反应。
Mult Scler Relat Disord. 2022 Jan;57:103382. doi: 10.1016/j.msard.2021.103382. Epub 2021 Nov 9.
8
The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy.炎症性肠病中抗TNF治疗增强了对SARS-CoV-2疫苗接种的T细胞反应。
Inflamm Bowel Dis. 2022 Jul 1;28(7):1130-1133. doi: 10.1093/ibd/izac071.
9
Long-lasting T-cell response to SARS-CoV-2 antigens after vaccination-a prospective cohort study of HCWs working with COVID-19 patients.接种疫苗后对 SARS-CoV-2 抗原的持久 T 细胞应答：一项与 COVID-19 患者一起工作的 HCWs 的前瞻性队列研究。
Infect Dis (Lond). 2023 Feb;55(2):142-148. doi: 10.1080/23744235.2022.2142662. Epub 2022 Nov 11.
10
Divergent SARS-CoV-2-specific T cell responses in intensive care unit workers following mRNA COVID-19 vaccination.mRNA COVID-19 疫苗接种后 ICU 工作人员中 SARS-CoV-2 特异性 T 细胞反应的差异。
Front Immunol. 2022 Oct 6;13:942192. doi: 10.3389/fimmu.2022.942192. eCollection 2022.

引用本文的文献

1
Immune profiling of responses to influenza vaccination in patients with myeloproliferative neoplasms.骨髓增殖性肿瘤患者对流感疫苗接种反应的免疫谱分析。
EJHaem. 2024 Apr 11;5(3):573-577. doi: 10.1002/jha2.868. eCollection 2024 Jun.
2
SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies.SARS-CoV-2 疫苗在血液系统恶性肿瘤患者中诱导的体液和细胞免疫。
Semin Hematol. 2022 Oct;59(4):192-197. doi: 10.1053/j.seminhematol.2022.11.001. Epub 2022 Nov 19.
3
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis.

本文引用的文献

1
Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron.疫苗引发针对 SARS-CoV-2 奥密克戎的高度保守的细胞免疫。
Nature. 2022 Mar;603(7901):493-496. doi: 10.1038/s41586-022-04465-y. Epub 2022 Jan 31.
2
Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.免疫后血清对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎B.1.1.529变体的中和作用降低。
Lancet. 2022 Jan 15;399(10321):234-236. doi: 10.1016/S0140-6736(21)02844-0. Epub 2021 Dec 20.
3
Serum antibody response in patients with philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines.
免疫原性和与血液恶性肿瘤患者在接种 SARS-CoV-2 疫苗和加强针后免疫反应受损相关的风险：一项更新的荟萃分析。
Blood Cancer J. 2022 Dec 23;12(12):173. doi: 10.1038/s41408-022-00776-5.
4
Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study.酪氨酸激酶抑制剂不会促进慢性髓性白血病患者接种BNT162b2疫苗后抗SARS-CoV-2刺突蛋白IgG水平下降：一项前瞻性观察研究。
Vaccines (Basel). 2022 Aug 27;10(9):1404. doi: 10.3390/vaccines10091404.
接种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白信使核糖核酸（mRNA）疫苗后，费城染色体阳性或阴性骨髓增殖性肿瘤患者的血清抗体反应。
Leukemia. 2021 Dec;35(12):3578-3580. doi: 10.1038/s41375-021-01457-1. Epub 2021 Nov 5.
4
Correlation between a quantitative anti-SARS-CoV-2 IgG ELISA and neutralization activity.抗 SARS-CoV-2 IgG ELISA 定量检测与中和活性的相关性。
J Med Virol. 2022 Jan;94(1):388-392. doi: 10.1002/jmv.27287. Epub 2021 Aug 31.
5
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局：一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
6
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms.单剂量BNT162b2 mRNA新冠疫苗可在骨髓增殖性肿瘤患者中诱导出高频率的中和抗体及多功能T细胞反应。
Leukemia. 2021 Dec;35(12):3573-3577. doi: 10.1038/s41375-021-01300-7. Epub 2021 May 22.
7
Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients.一种联合 ELISA 检测方法的验证，用于检测轻度或中度非住院患者对 SARS-CoV-2 的 IgG、IgA 和 IgM 抗体反应。
J Immunol Methods. 2021 Jul;494:113046. doi: 10.1016/j.jim.2021.113046. Epub 2021 Mar 26.
8
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19.在经典的骨髓增殖性肿瘤中，原发性血小板增多症与 COVID-19 期间静脉血栓栓塞的风险最高。
Blood Cancer J. 2021 Feb 4;11(2):21. doi: 10.1038/s41408-021-00417-3.
9
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib.COVID-19 伴骨髓增殖性肿瘤患者突然停用鲁索替尼后死亡率高。
Leukemia. 2021 Feb;35(2):485-493. doi: 10.1038/s41375-020-01107-y. Epub 2021 Jan 7.
10
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.两种基于 RNA 的新冠候选疫苗的安全性和免疫原性。
N Engl J Med. 2020 Dec 17;383(25):2439-2450. doi: 10.1056/NEJMoa2027906. Epub 2020 Oct 14.